Sidharth Kerkar
Founder & Chief Executive Officer AllerGene AI
Sid is a Pharma/Biotech leader and cell therapy innovator behind the discovery of MAGE-A as a pan-cancer target and next-generation T cell engineering with IL-12, now pioneering in vivo gene engineering to treat and prevent life-threatening allergies and anaphylaxis. Previous experience includes roles at Bristol Myers Squibb, Boehringer-Ingelheim Pharmaceutical, Eli Lilly & Company, Exuma Biotech
Seminars
Tuesday 15th September 2026
Panel Discussion: Investigating the Evolution of In Vivo Therapies to Accelerate Innovations
9:30 am
- Discussing the rapid progression of in vivo therapies, considering the impact on COGs and patient outcomes
- Highlighting in vivo innovations to develop more effective, scalable, and accessible therapies
- Evaluating what’s next for in vivo therapies to understand anticipated clinical progress, expanding disease indications and projected advancements for strategic planning
Tuesday 15th September 2026
Expanding CAR-T Therapies Beyond Cancer & Autoimmune Diseases into Mast Cell Diseases, Allergy & Immunology
12:00 pm
- Exploring the underlying pathology of allergic diseases
- Designing CAR-T therapies to eliminate mast cells, the cellular cause of allergic reactions
- Defining the unmet need for mast cell targeting CAR-T cells
Wednesday 16th September 2026
Session Chair:
Wednesday 16th September 2026
Panel Discussion: Aligning Preclinical Model Selection with Regulatory Expectations to Improve Translation & Approval Confidence
2:30 pm
- Evaluating mouse and non-human primate model translatability to improve clinical predictability
- Comparing model suitability across therapy types to highlight strategic differences that reduce regulatory risk
- Discussing gaps between required regulatory model data and biopharma efficacy needs to align development strategies with translational approval
